Hemostemix Inc. (CVE:HEM – Get Free Report) hit a new 52-week high on Monday . The stock traded as high as C$0.12 and last traded at C$0.12, with a volume of 60720 shares trading hands. The stock had previously closed at C$0.13.
Hemostemix Stock Performance
The business has a 50 day moving average of C$0.08 and a 200-day moving average of C$0.07. The company has a market capitalization of C$10.45 million, a P/E ratio of -6.00 and a beta of 0.20.
About Hemostemix
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia.
Featured Stories
- Five stocks we like better than Hemostemix
- What is the Dogs of the Dow Strategy? Overview and Examples
- Build-Your-Bowl Battle: CAVA, Chipotle, and Sweetgreen Face Off
- Best of the list of Dividend Aristocrats: Build wealth with the aristocrat index
- Insiders Are Loading Up: 3 Key Stock Picks for Investors
- Why Are These Companies Considered Blue Chips?
- How Cigna Remains at the Top of the Health Insurance Food Chain
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.
